Perspective Therapeutics (NYSE:CATX) Stock Rating Reaffirmed by Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reaffirmed by Royal Bank of Canada in a research note issued on Friday, Benzinga reports. They presently have a $3.00 price target on the stock. Royal Bank of Canada’s target price points to a potential upside of 180.37% from the company’s current price.

Other research analysts also recently issued research reports about the company. Oppenheimer restated an “outperform” rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. Cantor Fitzgerald assumed coverage on Perspective Therapeutics in a research report on Thursday, May 9th. They set an “overweight” rating for the company. B. Riley lifted their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Finally, Lifesci Capital reiterated an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $1.90.

Perspective Therapeutics Price Performance

Shares of CATX opened at $1.07 on Friday. Perspective Therapeutics has a fifty-two week low of $0.21 and a fifty-two week high of $1.91. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98.

Shares of Perspective Therapeutics are scheduled to reverse split on the morning of Monday, June 17th. The 1-10 reverse split was announced on Monday, June 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, June 17th.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Wednesday, May 15th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. Perspective Therapeutics had a negative return on equity of 46.38% and a negative net margin of 302.70%. The business had revenue of $0.33 million during the quarter. As a group, equities analysts predict that Perspective Therapeutics will post -0.11 EPS for the current year.

Insider Buying and Selling

In other news, CEO Johan M. Spoor bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The stock was bought at an average price of $1.17 per share, for a total transaction of $117,000.00. Following the transaction, the chief executive officer now directly owns 137,572 shares of the company’s stock, valued at approximately $160,959.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Robert F. Williamson III purchased 30,031 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were acquired at an average cost of $1.33 per share, with a total value of $39,941.23. Following the purchase, the director now directly owns 368,792 shares of the company’s stock, valued at $490,493.36. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Johan M. Spoor purchased 100,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $117,000.00. Following the completion of the purchase, the chief executive officer now directly owns 137,572 shares in the company, valued at $160,959.24. The disclosure for this purchase can be found here. Insiders bought 244,283 shares of company stock worth $317,849 in the last quarter. 3.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $15,511,000. Affinity Asset Advisors LLC purchased a new position in shares of Perspective Therapeutics during the first quarter valued at approximately $6,069,000. HighTower Advisors LLC purchased a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $314,000. Finally, Taylor & Morgan Wealth Management LLC increased its stake in shares of Perspective Therapeutics by 8.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after buying an additional 50,000 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.